Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 31, Issue 6, 2016, Pages 944-952

  Almquist, Tora ^a,b   Mobarrez, Fariborz ^a,b   Jacobson, Stefan H ^b   Wallén, Håkan ^b   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

Author keywords

cardiovascular; CKD; diabetes mellitus; statins; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CD40 LIGAND; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EZETIMIBE; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PLACEBO; SIMVASTATIN; THROMBOPLASTIN; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; SELP PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL STRUCTURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIAL MICROPARTICLE; FEMALE; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MONOCYTE; MONOCYTE MICROPARTICLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; COMPLICATION; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; RISK FACTOR;

AGED; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; CROSS-OVER STUDIES; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SIMVASTATIN;

EID: 84975116953     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv337     Document Type: Article

References (44)

1. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495
2. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105 (Suppl 1): S43-S54
3. Lutz J, Menke J, Sollinger D et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant 2014; 29: 29-40
4. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138
5. Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253
6. Shantsila E, KamphuisenPW, Lip GY. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010; 8: 2358-2368
7. Mobarrez F, Sjovik C, Soop A et al. CD40L expression in plasma of volunteers following LPS administration: a comparison between assay of CD40L on platelet microvesicles and soluble CD40L. Platelets 2015; 26: 486-490
8. Burger D, Schock S, Thompson CS et al. Microparticles: biomarkers and beyond. Clin Sci 2013; 124: 423-441
9. Owens AP, III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-1297
10. Amabile N, Guerin AP, Leroyer A et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 16: 3381-3388
11. Amabile N, Guerin AP, Tedgui A et al. Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant 2012; 27: 1873-1880
12. FaureV,Dou L, Sabatier F et al. Elevation of circulating endothelialmicroparticles in patients with chronic renal failure. J ThrombHaemost 2006; 4: 566-573
13. Ando M, Iwata A, Ozeki Y et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002; 62: 1757-1763
14. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016
15. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696
16. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
17. Bonetti PO, Lerman LO, Napoli C et al. Statin effects beyond lipid lowering -are they clinically relevant? Eur Heart J 2003; 24: 225-248
18. Kalogirou M, Tsimihodimos V, ElisafM. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 2010; 633: 62-70
19. Almquist T, Jacobson SH, Lins PE et al. Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial. Nephrol Dial Transplant 2012; 27: 3540-3546
20. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
21. Mobarrez F, He S, Broijersen A et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on plateletderived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106: 344-352
22. Lacroix R, Judicone C, Poncelet P et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost 2012; 10: 437-446
23. Almquist T, Jacobson SH, Mobarrez F et al. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest 2014; 44: 276-284
24. Woo JS, Kim W, Lee SR et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a highmaintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J 2011; 162: 1018-1025
25. Gremmel T, Muller M, Steiner S et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant 2013; 28: 2116-2122
26. Yagmur E, Frank RD, Neulen J et al. Platelet hyperaggregability is highly prevalent in patients with chronic kidney disease: an underestimated risk indicator of thromboembolic events. Clin Appl Thromb Hemost 2015; 21: 132-138
27. Nomura S, Shouzu A, Omoto S et al. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004; 10: 133-141
28. SommeijerDW, Joop K, Leyte A et al. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 2005; 3: 1168-1171
29. Suades R, Padro T, Alonso R et al. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost 2013; 110: 366-377
30. Tehrani S, Mobarrez F, Antovic A et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 2010; 126: e225-e231
31. Antoniades C, Bakogiannis C, Tousoulis D et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-677
32. Owens AP III, Byrnes JR, Mackman N. Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends Cardiovasc Med 2014; 24: 95-98
33. Osterud B. Tissue factor/TFPI and blood cells. Thromb Res 2012; 129: 274-278
34. Camargo LM, Franca CN, IzarMCet al. Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy. Braz J Med Biol Res 2014; 47: 432-437
35. Lins LC, Franca CN, Fonseca FA et al. Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys 2014; 70: 687-696
36. Morrone D, Weintraub WS, Toth PP et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251-261
37. Ballantyne CM, Blazing MA, King TR et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487-1494
38. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-2397
39. Palmer SC, Craig JC, Navaneethan SD et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 263-275
40. Mobarrez F, Egberg N, Antovic J et al. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebocontrolled study. Thromb Res 2012; 129: 95-97
41. Tehrani S, Mobarrez F, Lins PE et al. Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes. Diab Vasc Dis Res 2013; 10: 483-488
42. Diamant M, Tushuizen ME, Abid-Hussein MN et al. Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost 2008; 100: 489-497
43. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: II18-II26
44. Mobarrez F, Antovic J, Egberg N et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res 2010; 125: e110-e116